Neuroinflammation following anti-parkinsonian drugs in early Parkinson's disease: a longitudinal PET study.

ABSTRACT: The progression of neuroinflammation after anti-parkinsonian therapy on the Parkinson's disease (PD) brain and in vivo evidence of the therapy purporting neuroprotection remain unclear. To elucidate this, we examined changes in microglial activation, nigrostriatal degeneration, and clinical symptoms longitudinally after dopamine replacement therapy in early, optimally-controlled PD patients with and without zonisamide treatment using positron emission tomography (PET). We enrolled sixteen PD patients (Hoehn and Yahr stage 1-2), and age-matched normal subjects. PD patients were randomly divided into two groups: one (zonisamide⁺) that did and one (zonisamide^-) that did not undergo zonisamide therapy. Annual changes in neuroinflammation ([¹¹C]DPA713 PET), dopa

SUBMITTER: Terada T 

PROVIDER: S-EPMC10897150 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature